Patterson Companies, Inc. (NASDAQ: PDCO) Q2 2021 earnings call dated Dec. 02, 2020
Corporate Participants:
John M. Wright — Vice President of Investor Relations
Mark Walchirk — President and Chief Executive Officer
Don Zurbay — Chief Financial Officer
Analysts:
John Kreger — William Blair. — Analyst
Michael Cherny — Bank of America — Analyst
Jeff Johnson — Baird — Analyst
Erin Wright — Credit Suisse — Analyst
Glen Santangelo — Guggenheim Securities — Analyst
Kevin Caliendo — UBS — Analyst
Kevin Kedra — G.research — Analyst
Jon Block — Stifel — Analyst
Jason Bednar — Piper Sandler — Analyst
Nathan Rich — Goldman Sachs — Analyst
Presentation:
Operator
Ladies and gentlemen, thank you for standing by and welcome to Patterson Companies Second Quarter Fiscal Year 2021 Earnings Call. [Operator Instructions] I’d now like to hand the conference over to your speaker today, John Wright, Vice President, Investor Relations. Thank you. Please go ahead, sir.
John M. Wright — Vice President of Investor Relations
Thank you, operator. Good morning, everyone, and thank you for participating in Patterson Companies fiscal 2021 second quarter earnings conference call.
Joining me today are Patterson’s President and Chief Executive Officer, Mark Walchirk; and Patterson’s Chief Financial Officer, Don Zurbay. After a review of the fiscal 2021 second quarter by management, we will open the call to your questions.
Before we begin, let me remind you that certain comments made during this conference call are forward-looking in nature and subject to certain risks and uncertainties. These factors, which could cause actual results to materially differ from those indicated in such forward-looking statements are discussed in detail in our Form 10-K and our other filings with the Securities and Exchange Commission. We encourage you to review this material. In addition, comments about the markets we serve, including growth rates and market shares are based upon the company’s internal analysis and estimates. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast December 2, 2020. Patterson undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.
Also, a financial slide presentation can be found in the Investor Relations section of our website at pattersoncompanies.com. Please note that in this morning’s conference call, we will reference our adjusted results for the second quarter of fiscal 2021. The reconciliation table in our press release is provided to adjust reported GAAP measures, namely operating income, income before taxes, income tax expense, net income, net income attributable to Patterson Companies, Inc., and diluted earnings per share attributed to Patterson Companies, Inc. for the impact of deal amortization, integration and business restructuring expenses, legal reserve costs, accelerated debt-related costs and an investment gain, along with the related tax effects of these items. We will also discuss free cash flow as defined in our earnings release, which is a non-GAAP measure, and use the term internal sales to represent net sales adjusted to exclude the impact of foreign currency. The reconciliation of our reported and adjusted results can be found in this morning’s press release. These non-GAAP measures are not intended to be a substitute for our GAAP results.
This call is being recorded and will be available for replay starting today at noon Central Time, for a period of one week.
Now, I’d like to hand the call over to Mark Walchirk.
Mark Walchirk — President and Chief Executive Officer
Thank you, John, and welcome, everyone, to Patterson’s fiscal 2021 second quarter earnings conference call. First off, I hope you and your families, all had a happy and safe Thanksgiving and that everyone is staying healthy amidst the evolving coronavirus trends.
Patterson achieved very strong performance in the second quarter of fiscal 2021. Our results reflect the resilience of our business and our customers and the continued momentum from our focused investments to drive sales execution and operational excellence across our platform.
Even amidst the continued challenges due to the COVID-19 pandemic, our team performed at a very high level. We are leveraging our differentiated value proposition and providing trusted guidance and expertise to our customers, while also deepening our relationships with our manufacturing partners.
Before we dive into the details, let me touch on several of the key highlights from the quarter. First, on a year-over-year basis, internal sales grew 9%. This included internal sales growth of 12% in Dental and 7% in Animal Health. Second, we grew our adjusted operating margin year-over-year by 130 basis points to 5.3%. Third, we delivered adjusted earnings of $0.63 per share, representing an increase of 62% over the prior year period. Fourth, we continued momentum on our top and bottom line, has further strengthened our balance sheet and overall financial position.
And importantly, we maintained our focus on the core principles that have helped guide our response throughout the COVID-19 pandemic, protecting the health and safety of our employees, ensuring business continuity and support for our customers, and doing our part to help reduce the spread of the virus in our communities. As cases are unfortunately rising across the world, we remain committed to adhere to these principles and confident they will help us continue to safely and effectively navigate through this period.
Our results this quarter are not simply the product of our team’s great work during the past three months. They instead reflect the consistent and focused approach we have taken over the past several years to drive improved sales execution, operational excellence, effective mix management, expense discipline and working capital improvement, all while making targeted investments to deepen our value proposition, build our culture and deliver an outstanding customer experience.
Our enterprise-wide commitment to improving these core foundational elements has enabled Patterson to stabilize and build momentum in our businesses, strengthen our balance sheet and capitalize on opportunities to outperform in our end markets. We are creating a stronger Patterson that is well positioned to deliver enhanced value for all our key stakeholders.
With that overview, I will now drill down a bit deeper into the performance drivers in each of our segments during the second quarter. In our Dental segment, as I mentioned earlier, internal sales increased 12%, driven by strong sales growth in all three categories: Consumables, Equipment, and value-added services. This performance reflects the continued recovery of the Dental market from the earlier closures at the onset of the pandemic. Unfortunately, this market recovery has been faster and broader than we expected.
The market recovery combined with our strong sales and service execution, as we believe, allowed us to outperform the industry and increase our market share. When dental offices safely reopened after widespread shutdown, patients returned, driving increased demand for dentistry and for Patterson’s range of products and value-added services.
We’re hearing from our customers that their patients are comfortable visiting their dental practices again with the enhanced infection control procedures, screening protocols and safe patient-communication tools our customers have implemented.
Patterson’s ability to serve as a comprehensive value-added provider of consumables, equipment, practice management software and technology service and support made us a critical partner for our customers as they reopened and ramped back up their practices. Further, our decision to fully maintain our customer-facing sales and support teams throughout the pandemic, provided tremendous support to our customers as they navigated this new operating environment.
Our Dental business delivered year-over-year internal sales growth of nearly 18% in the Consumables category and it is worth noting that our sales growth of Consumables was fairly consistent across all three months of our fiscal second quarter. As expected, a key contributor of this growth was increased sales of infection control products, including masks, gowns, gloves, face shields and disinfectants that are more essential in dental practices today than they were prior to the onset of the pandemic.
In our fiscal second quarter, approximately two-thirds of the 18% year-over-year growth in Consumables was driven by increased sales of infection control products. However, even after the anticipated widespread distribution of a safe and effective COVID-19 vaccine, we believe there has been a permanent shift in the expectations for infection control measures for dental practices going forward.
While demand for infection control products may moderate from the current levels over time, we expect the new normal to remain well above pre-pandemic demand levels over the long term as dentists and their patients embrace this new standard-of-care. More importantly, our year-over-year sales growth in the Consumables category extended beyond the increased sales of infection control products. In fact, if you exclude the sales growth contribution from infection control products, we delivered approximately 6% year-over-year sales growth in our non-infection control consumables products.
We believe this healthy mid-single-digit growth of non-infection control products is due to the continued investments we’ve made in our field sales and support teams, which is driving market share gains and increased enrollment in Patterson Advantage customer rewards loyalty program.
Our Advantage program has made it easier and more affordable for our customers to invest in their own practice growth with benefits in equipment repair, service and support and other awards.
During the quarter, we also continued to see increasing demand for our expanding and highly profitable private label portfolio of products. The strength of our Consumables business combined with our expectation of elevated demand for infection control products going forward, and the gains achieved from our customer engagement and retention programs, gives us confidence in our long-term positioning in the Consumables category.
Internal sales of equipment grew over 5% in the second quarter led by double-digit growth in the core equipment and digital technology categories. We are very pleased with these results, especially given that beginning in October, we began a difficult equipment comparison with the same period last year. As a reminder, last year, during the second quarter of fiscal 2020, we delivered 12% year-over-year growth in overall equipment sales. That performance was primarily driven by growth in the CAD/CAM category through our strong sales execution, following the introduction of several innovative new products.
The success of our efforts last year also drove strong performance in the third and fourth quarters, which will create a more challenging comparison for the balance of this fiscal year, particularly in the CAD/CAM category. However, our second quarter equipment results demonstrate that our customers remain committed to investing in their practices and believe in the future of the market and their businesses.
Due to the pandemic, we have adapted to find new and creative ways to collaborate with our manufacturing partners on financing strategies, education initiatives, online training and prominent social media and online events. Patterson continues to be the partner of choice in delivering new product launches and technology integration in today’s modern dental office environment.
As you know, Patterson’s expertise in dental equipment and technology integration starts well before and continues well after the initial sale. We have the unique ability to support our customers throughout the entire lifecycle of their equipment and technology investments, which we believe is a distinct competitive advantage and an important driver of our overall value proposition.
We are very encouraged by the recovery and resiliency of the dental market in calendar 2020. Facing serious challenges, dentists have proactively and enthusiastically adapted to operating in this new environment, ensuring that their patients feel safe in their practices.
We are proud to be a part of helping our customers succeed in this environment and we’ll continue to focus on our core operational principles, strong execution, operational excellence and leveraging our differentiated value proposition to help drive practice success.
Turning now to Animal Health. Our Animal Health segment generated total internal sales growth of 7% during the second quarter, led by strong internal sales growth of nearly 12% in our Companion Animal business. Our top line results in Companion Animal, underscore the underlying strength of the pet market realized from increased pet ownership and spending as well as new product innovation.
Our Animal Health sales teams have done an incredible job, ensuring that their customers have access to a broad array of products and prescription medications, technologies and services to help their practices succeed in the face of increased market demand. Our field reps, inside sales and support teams work collaboratively every day with our customers through multiple touch points.
We also continue to leverage deep relationships with our preferred manufacturing partners to develop strategic business plans that are aligned with our respective goals and objectives and drive value across the supply chain.
Looking ahead, we believe the growth of pet ownership rates that has occurred over the past few quarters is unlikely to continue at the current rate. However, while these growth rates may stabilize, going forward, we believe the overall Companion Animal market with our veterinary customers at the center will grow at a faster rate than prior to the pandemic, enhancing the growth opportunity for our Companion Animal business over the long term.
On the Production Animal side, internal sales in the second quarter turned positive, growing 2% on a year-over-year basis as the market continued to recover from the prior disruption caused by COVID-19. One factor worth noting that positively impacted our second quarter performance, is the shift of the fall cattle run, and movement to feed yards earlier in the year. As a result, some sales volume moved from our fiscal third quarter into the second quarter.
We are pleased with these improving top line results in the production market but expect the timing benefit from the earlier fall run may create a more challenging production animal comparison during our fiscal third quarter.
As a reminder, on last quarter’s call, we discussed supply chain challenges in the swine market associated with the shutdown of packing plants due to COVID-19 outbreaks. While beef and pork packing plants are currently operating and processing near capacity, they have not yet been able to catch up with inventory at the producer level.
As the pandemic continues to spread in parts of the U.S., where many packing plants operate, we are working closely with our customers to support their continuing operations. While any significant pandemic-related supply chain disruption could further impact the backlog of market-ready animals being held in production facilities, particularly in the swine market, we believe packing plants have enhanced safeguards in place and are better equipped to more effectively address any impact than they were earlier in the year.
We are pleased with the results in our Animal Health segment despite some expected variability in the production market dynamics, and we are confident in our full-service and support value proposition will continue to position Patterson as an indispensable and trusted partner for both our Companion and Production Animal customers.
Before turning it over to Don, I would like to touch briefly on our ongoing response to COVID-19. As I mentioned earlier, the rise of COVID cases points to the need to stay vigilant in our safety measures and risk mitigation efforts. In keeping with our COVID principles, we continue to follow our comprehensive health and safety protocols, including working-from-home where possible, mask wearing, temperature checks, reducing close contact in our operations and proactive deep cleanings at our facilities.
While our facilities remain open and fully operational, we have specific plans in place to ensure we can continue to support our customers should our operations be directly impacted due to COVID-19. We are also working closely with all our industry partners to help ensure the safety of our customers’ operations, so they can continue to provide their vital and essential services.
As we have throughout this pandemic, Patterson is prepared to continue to support our teams and our customers as the situation evolves.
And with that, I’ll turn the call now over to Don for a deeper dive into our financial results.
Don Zurbay — Chief Financial Officer
Thank you, Mark, and good morning, everyone. Consolidated reported sales for Patterson Companies in our fiscal 2021 second quarter were approximately $1.6 billion, an increase of 9.5% versus the second quarter a year ago.
Internal sales, which are adjusted for the effects of currency translation, increased 9.0% compared to the same period last year.
As Mark mentioned, we believe our results this quarter can be directly attributed to the investments we have made in our business and the focus and commitment of our people to deliver these outstanding results.
Our second quarter adjusted gross margin was 20.6%, which was down 90 basis points versus the second quarter of fiscal 2020. Dental gross margins were slightly impacted by higher delivery costs related to COVID-19. And on the Animal Health side of the business, unearned calendar year rebate dollars in the Production Animal business also contributed to lower gross margin.
However, we consider these factors to be somewhat temporary in nature and believe the strength of our full-service value proposition will continue to support our gross margins for the long term.
Adjusted operating expenses as a percentage of net sales for the second quarter were 15.3% and favorable by 220 basis points on a year-over-year basis. Last quarter, we discussed the expense savings related to salary reductions, furloughs and reduced work hours that ended in Q1, with those expenses coming back into the P&L in future quarters. While that impact has occurred just as we stated, we have continued to benefit from ongoing expense discipline and from leveraging our cost structure over higher sales volumes.
In the fiscal second quarter, our consolidated adjusted operating margin was 5.2%. This represents a 130-basis point improvement over the same period in the prior year. As you recall, our consolidated adjusted operating margin has improved for a number of quarters, posting year-over-year improvement for each of the past seven quarters as a result of our efforts to drive operational improvements and expense discipline, along with the added impact of segment mix and the leveraging of higher sales volume.
We continue to be encouraged about our year-over-year margin improvement for another quarter. Our adjusted tax rate for the second quarter was 23.7%, which was a decrease of 100 basis points compared to the second quarter of the prior year.
Reported net income attributable to Patterson Companies, Inc. for the second quarter of fiscal 2021 was $54.1 million or $0.56 per diluted share. This compares to a reported net loss of $33.1 million or $0.35 per diluted share in the second quarter, one year ago.
Adjusted net income attributable to Patterson Companies in the second quarter, which excludes deal amortization, integration and business restructuring expenses, legal reserve costs and accelerated debt-related costs totaled $61.1 million or $0.63 per diluted share. This compares to $36.6 million or $0.39 in the second quarter of fiscal 2020 and represents a $0.24 or 62% year-over-year increase. This increase over the prior year is primarily attributed to our strong sales execution, improved mix and the benefit of continued operating expense discipline.
Now, let’s turn to our business segments, starting with our Dental business. In the second quarter of fiscal 2021, internal sales for our Dental business increased 12.1% compared to the second quarter of fiscal 2020. On that same basis, Patterson sales of consumable dental supplies were up 17.7% with strong growth in both infection control products and our base consumables category.
Internal sales of equipment in the second quarter increased 5.4% versus the same period a year ago, led by strong growth in core equipment and digital equipment categories. For modeling purposes, keep in mind that we had very strong equipment sales in fiscal 2020 and we will be coming up against a difficult year-over-year comparison for the coming third and fourth quarters of fiscal 2021. And finally, internal sales of software and value-added services increased 5.6% in the fiscal second quarter.
Adjusted operating margins in Dental were 11.7% in the second quarter, a 190-basis point improvement compared to the prior year. While we did experience increased freight and delivery costs related to COVID-19 in the fiscal second quarter, we also benefited from the expense leverage related to the increased sales volume as well as continued operating expense discipline.
Now, let’s move on to our Animal Health segment. During the fiscal second quarter, internal sales for our Animal Health business were up 6.9% compared to the same period a year ago. Increased pet adoptions and increased attention to pets, along with our strong sales execution drove our improved performance in the quarter versus the same period one year ago.
Adjusted operating margins in our Animal Health segment were 2.9% in the fiscal second quarter, a decrease of 60 basis points compared to the second quarter of the prior year as lower operating expenses were offset by lower gross margins, primarily due to less rebates earned calendar year-to-date within our Production Animal business and slightly lower point-of-sale margins in our Companion Animal business.
Now, let’s look at several cash flow and balance sheet items. During the first six months of fiscal 2021, we used $423 million in cash from operating activities. We also collected deferred purchase price receivables of $409 million during the year, which is included in the investing activities section of the cash flow statement.
To fully understand our free cash flow, the total of these two amounts as a use of cash for the first six months of fiscal 2021 are $14 million. Free cash flow, which we have explained and calculated in the table within our press release, decreased $203 million during the second quarter of fiscal 2021 compared to fiscal 2020.
The year-over-year decrease is primarily due to elevated levels of accounts payable at the beginning of the fiscal year due to COVID-19 as we carefully managed our cash and which is normalized during the first two quarters of fiscal 2021.
Turning to capital allocation. We continued to execute on our strategy to return cash to our shareholders. In the second quarter of fiscal 2021, we declared a quarterly cash dividend of $0.26 per diluted share, which was then paid during the first week of the third quarter of fiscal 2021. On a year-to-date basis, Patterson has returned $25 million in cash dividends to our shareholders.
Our Board continues to view our dividend as an important component of returning value to our shareholders. And the current dividend yield provides a meaningful baseline return to shareholders as we continue focusing on our plans to drive improved performance in the business.
Let me conclude with some comments on our outlook for fiscal 2021. Due to the continued uncertainty surrounding the COVID-19 pandemic and its potential impact on business operations, we are not providing fiscal 2021 financial guidance at this time.
And now, I will turn the call back over to Mark.
Mark Walchirk — President and Chief Executive Officer
Thanks, Don. As we look ahead, I am enthusiastic about our position in each of our end markets and confident in Patterson’s long-term value creation potential. We have the right team and the right strategy in place to capitalize on the positive fundamental opportunities of our end markets over the long term, while also being well prepared to manage through potential changes in the near-term market dynamics.
While our near-term focus remains centered on driving execution and supporting our customers through the pandemic, we are also looking ahead to the future and excited about the opportunities that exist. Our ongoing actions to strengthen our financial position have created improved balance sheet flexibility, which puts us in a strong position to consider strategic investments that will accelerate future growth and value creation.
Before we wrap up, I want to take a moment to express my gratitude for the hard work, passion and focus of the 7,000 plus members of the Patterson team. I am incredibly proud of how our team has stepped up to support our customers and business partners these past nine months and I am confident our “We are Patterson” spirit is one of the key ingredients to our success.
I also want to thank our customers and acknowledge their tremendous resiliency during these challenging times. It’s a privilege to serve them and to do our part to help them succeed.
That concludes our prepared remarks, and Don and I will be glad to take your questions. Operator, please open the line.
Questions and Answers:
Operator
[Operator Instructions] Your first question comes from John Kreger from William Blair. Please go ahead. Your line is open.
John Kreger — William Blair. — Analyst
Hi, guys. Thank you for the questions. Don, you called out tougher comparisons over the next couple of quarters. Anything else that we should be thinking about in terms of the sustainability of the great progress you guys had in the fiscal second quarter?
Don Zurbay — Chief Financial Officer
No, I think the biggest thing we wanted to make sure that you don’t tend to your models was just the outstanding equipment sales we had last year in the third and fourth quarter and the tough comp.
John Kreger — William Blair. — Analyst
Okay, great. And specifically, the 5.3% EBIT, do you think that’s sustainable as you layer in some of the temporary cost cuts?
Don Zurbay — Chief Financial Officer
Yes, John. So, hopefully you can appreciate we’re just trying to maintain some discipline on not really giving too much guidance. I think if you look at the factors that drove the operating margin improvement though, over the last seven quarters, so expense discipline, segment mix, leveraging our cost structure over higher sales volume, private label initiatives, I think these are all things that we would point to as being sustainable impacts that should continue to help us sustain or improve our margin as we keep moving forward.
John Kreger — William Blair. — Analyst
Okay, thanks. And then one more. As we see cases go up quite a bit in the U.S., what impact are you seeing particularly in Dental? Are you seeing any practices either closed or see declining volumes? Thanks.
Mark Walchirk — President and Chief Executive Officer
Yes, John. This is Mark. Maybe I’ll take that one. Thanks for the question. Certainly, to this point, we have not seen and we do not expect any broad shut down of dental offices, I think really for a couple of key reasons. First, we believe it’s very safe to go to dentist due to all the precautions that are being taken to really help ensure the safety of the patients and staff.
And second, we believe strongly that going to the dentist is critically important and that oral health is obviously such a key element in overall patient health.
So while we obviously have seen some recent uptick in cases and we’re hearing of potential State and local actions that maybe taken, which could have a perhaps modest effect in some geographies, we’re certainly not anticipating any type of broad shut down. And looking forward, while it’s difficult to predict, I think, exactly what’s going to happen in the coming months due to the current environment, I can tell you our team is very focused on continuing the progress that we’ve been making and building on our momentum.
John Kreger — William Blair. — Analyst
Great. Thank you.
Operator
Your next question comes from Michael Cherny from Bank of America. Please go ahead. Your line is open.
Michael Cherny — Bank of America — Analyst
Thanks so much for the question. Congratulations on a really nice quarter. Maybe driving into one of John’s question little bit further with regards to the operating expenses and the strong margin performance. Mark, as you think about the actions that the organization has taken basically since you started, how far along the pathway you think you are in terms of checking all the boxes on the modernization efforts, some of the cost redundancy that you want as you think about the next three to five years of Patterson’s growth potential?
Mark Walchirk — President and Chief Executive Officer
Yes, Michael. Thank you. Well, first of all, I think there is continued opportunity for us to show progress and continue to execute against many of the things that we’ve talked about on the call, sales execution, expense discipline, operational excellence, building out our private label portfolio, continuing to expand our value proposition, drive our Equipment and Technology Services segment, building out our software capabilities. So, I think there is still a lot to do.
We’re very pleased with the progress that we’ve made. But certainly, we believe we have a lot of opportunity to continue to progress going forward. And I think also, as I indicated, we’re in a position now. I think given the progress, we’re obviously very heads down focused on the near term and the continued implications of the pandemic, but we’re also looking further down the line and thinking about ways that we can accelerate our growth, expand and strengthen our value proposition, continue to build scale in the business.
And so again, we feel very good about the progress we’re making. We have opportunity and more work to do to continue our progress and we think there is also opportunities for us to accelerate our growth going forward through strategic and targeted investments.
Don Zurbay — Chief Financial Officer
Michael, I might just add that — to Mark’s comments — I think the events over the last nine months with the pandemic have also given us, I’d say, new opportunities to look at different — our cost structure differently, that I think you could add to that mix of things that Mark mentioned.
Michael Cherny — Bank of America — Analyst
Thanks. And then just one more if I may. Diving in a little bit more on the 6% for Consumables growth that you had ex-PPE, you referenced uptake in the Advantage program as well as share gains. On the latter, on the share gain, in particular, what do you think some of the new customers that you are winning or maybe even old customers that you’re winning back, have they found most appealing about the current go-to-market offering versus what you may have been selling through or how you were positioned a couple of years ago?
Mark Walchirk — President and Chief Executive Officer
Yes, thank you. Look, as we indicated, we’re certainly — our growth is accelerating and that momentum is creating share gains in the market. We actually had pretty strong momentum coming into the pandemic and I think our team has just done a fantastic job of continuing that momentum, obviously during a pretty challenging period here. But I think again, this is the work that the team has been doing over the past several years and we’ve talked about it, sales and service execution, investments we’ve made in field productivity, I think, are really a distinct advantage we have around our Equipment and Technology portfolio and really the entire product lifecycle from start to finish, the tremendous support, collaborative support between our national support center, our local branch infrastructure, our service technicians, I just think our value proposition, we continue to invest in it. I think our customers continue to see the value from it and I think we also have an engaged and focused and motivated team. And then we’re really pleased, obviously, with the overall performance.
So, I think it’s really just a number of factors, Michael, and I think we’re executing against the things that we’ve been talking about for many quarters now.
Michael Cherny — Bank of America — Analyst
Great. Thank you.
Operator
Your next question comes from Jeff Johnson from Baird. Please go ahead. Your line is open.
Jeff Johnson — Baird — Analyst
Thank you. Good morning, guys. So, Mark, I just want to follow-up on that question on that 6% Consumables number. If there share gains in there, I’m sure that’s 5, 7 point, something like that of the growth. But how do you bridge the, let’s say, flat ex-share gains Consumables number somewhere in that ballpark? How do you bridge that with what seems to be pretty clearly volumes down across the industry, 15% or 20%, maybe even a little more than that if you believe some of the ADA data? Just how are you kind of getting into that flattish kind of core Consumables growth ex — accounting for those volume declines?
Mark Walchirk — President and Chief Executive Officer
Yes, Jeff, thanks. Look, I think again the key here is, we believe we’re outperforming the market and gaining share. And so I think that’s really point one. I think point two, certainly, we access a number of different data sources and we’re obviously trying to triangulate all the different data that’s out there. Based on our internal data, we actually believe patient demand levels are slightly higher than some of the external data sources are reporting. You layer in then the greater usage of infection control products. I think the higher mix of acuity visits versus hygiene visits, I think those are — all those factors are coming into play here.
But, look, net-net, we are seeing the results from our focused investments in our field sales and service teams and, frankly, from a very, I think, strategic and conscious decision that we made at the onset of the pandemic to fully maintain and retain our field sales and service organizations. And I think all those things tied into what we spoke of earlier with Michael, in terms of just the general focus on execution over the past many quarters, I think they’re all adding up to the performance that you’re seeing.
Jeff Johnson — Baird — Analyst
That’s helpful. Thank you. And Don, respecting kind of the tough comp commentary you had on CAD/CAM, especially coming out of DS World last year, the offset to that is obviously there seems to be, at least anecdotally, some increased interest in same day dentistry, given COVID concerns and all that. So, what is just kind of the general outlook and what you’re hearing in the channel about CAD/CAM demand in general? Again, understanding the comps are one thing you’ll have to hurdle the next couple of quarters, but generally, what are you seeing and hearing about CAD/CAM demand for maybe a longer-term perspective? Thanks.
Mark Walchirk — President and Chief Executive Officer
Maybe I’ll jump in and Don can add any color. I think your comment, Jeff, about single visit dentistry certainly is something we believe and certainly within this COVID environment even more important. Hard to predict the CAD/CAM specific demand drivers for the future, but we continue to see new and innovative products being launched in the marketplace. We believe that we provide a tremendous organization and execution ability in terms of driving sales and demand of those new and innovative products. We feel very good about kind of the full product lifecycle where we can support our customers in terms of their investments and their practices. And as we mentioned, we actually are continuing to see our dental practice invest in their practices and that gives us a lot of confidence in the future as well.
So we’re very focused on helping our customers see that value. We believe our lifecycle value proposition is a distinct competitive advantage for us and so we’re certainly very bullish on the long-term opportunity from new technology and innovation in the dental market.
Jeff Johnson — Baird — Analyst
Thank you.
Operator
Your next question comes from Erin Wright from Credit Suisse. Please go ahead. Your line is open.
Erin Wright — Credit Suisse — Analyst
Hey, thanks. Not sure if you can parse this out, but excluding the infection control product, can you speak to that monthly cadence that you called throughout the quarter, both I guess across Dental and Animal Health for that matter, and what you were seeing kind of on a monthly basis, what that exit run rate was?
Don Zurbay — Chief Financial Officer
Yes. Thanks, Erin. I think as we indicated on the call, we’re actually very pleased with the fact that the results that we shared were pretty consistent across the three months of the quarter and we’re obviously pleased with the momentum that we’re driving in our Consumables segment. I will tell you, just given the dynamics that we’ve been facing, great collaborative effort between our field sales, marketing, supply chain teams. And we’re also pleased with the momentum that we’ve seen continue in our Consumables segment into November.
And as we indicated, look, we do expect the demand for infection control products to moderate slightly from the current levels. But we also envision that that’s going to be a strong tailwind for us for the long term, just given kind of the new standard-of-care. We feel we’re very well positioned there. Many of our private label products happen to be in the infection control categories. So really some positive tailwinds for us there.
And then I think as it relates to kind of the trend line in November as well, in particular in our Companion business, we’re seeing good solid trends in November that we saw in the third — excuse me, our fiscal second quarter as well.
Erin Wright — Credit Suisse — Analyst
Okay. Great. Thanks. And then can you detail some of the dynamics impacting the Animal Health margins? Will you lap some of the unfavorable rebate dynamics? And also, can you speak to the lower margins and can [phonetic] — does that continue in the coming quarters?
Don Zurbay — Chief Financial Officer
Yes. Erin, I think that on the production side, most of those rebate programs are calendar year programs. So what we’re dealing with right now is just the — and just given the challenges in those, in that market earlier in the year, what we’re dealing with there is just needing to get to January 1st and kind of the new program with a improving sentiment in the production space.
On the Companion side, there was some slight margin, point-of-sale margin — margins were down slightly. That’s just a continuing dynamic that we keep working through with pressure in that space with our suppliers. And that’s really nothing new. I think it’s the same thing that we’re going to be battling for a while. But we — through all the other, the private label initiatives, etc., we think we have a way of managing through that.
Mark Walchirk — President and Chief Executive Officer
And then I would just add one quick comment there, I think with regard to just some of the manufacturing dynamics that Don outlined. Look, our focus is working strategically with our preferred manufacturer partners really across all of our business, but speaking in particular here to the Companion Animal segment, those manufacturers that understand the value that we provide throughout the supply chain and the excess and the impact we have with our vet hospital customers to impact and move share. In fact, we’ve actually seen our growth where we put joint business plans into place with specific preferred manufacturers. We’ve seen our growth outpaced the growth of others.
So we’re very confident in the critical role we play in the supply chain and we’re going to continue to focus our sales and marketing efforts and work closely with those preferred partners where we can bring joint value to our customers and drive good margins for both companies.
Erin Wright — Credit Suisse — Analyst
Excellent. Thank you.
Operator
Your next question comes from Glen Santangelo from Guggenheim Securities. Your line is open.
Glen Santangelo — Guggenheim Securities — Analyst
Thanks for taking my question. Hey, Mark, I just want to follow-up on some of your commentary on the equipment side. If I heard you correctly, I thought you said that both the core equipment and the digital technology are both up sort of double digits in the quarter and I’m trying to reconcile that versus the organic number of just over sort of 5% in the equipment side and I’m trying to put that into context with the comments you just made on February. I think I heard you mentioned that Consumables sort of continued into November, but I didn’t hear you mentioned anything about Equipment. Thanks.
Mark Walchirk — President and Chief Executive Officer
Yes, Glen. Thanks. And maybe Don can comment on just the — what we specifically outlined in the call. And as I indicated just given the real strong Q2 from last year, we’re actually really pleased with our overall growth in equipment in our 2Q this year. And we specifically called out kind of that core equipment category as well as CAD/CAM, and we do obviously have other categories of equipment to get to your question.
I think we — as we indicated, we do have a tough comp in Q3 and we’re certainly obviously aware of that. And look, I think as we’ve said a number of times on these calls, obviously our Equipment volume can be a little bit lumpy, if you will, over time. But I would say in general, we’re very pleased with our equipment performance year-to-date. Our teams have a great funnel and strong backlog of equipment here as we head into the back half. And again, I think what we believe is a distinct competitive advantage that we have, we’re seeing that play out in the marketplace and we’re very pleased with our performance there.
Glen Santangelo — Guggenheim Securities — Analyst
Maybe if I could just ask one more question on the 6% growth in the core consumables. I think what we’re all trying to understand is where the market is at this point? I think on your prepared remarks, you said you’re outperforming the industry, but we — you also sort of mentioned there was some pent-up demand and some higher acuity visits that may be a small tailwind for those — to those numbers you generated this quarter; plus, I’m guessing there were some inventory normalization that happened during the quarter. So can you just give us a sense, is the market back to flat or is it still sort of trailing year-over-year? And did inventory normalization play a factor in the results this quarter?
Mark Walchirk — President and Chief Executive Officer
Yes, look, first of all, I would not feel like there is any significant impact here from pent-up demand. I think we’re driving the performance that we indicated as a result of what has been a very strong market recovery so far in the Dental segment, frankly faster and broader than I think we would have anticipated three or six months ago, and really strong sales and service execution from our team. And so I think those are really the key factors.
Yes, Consumables benefited from strong growth in infection control products. But as we indicated, our non-infection control product categories grew approximately 6%. So I think that is a very good indicator of the fact that we are executing against our plans, and we’re very focused on continuing to drive that Consumables category.
And look, I think it’s difficult for us to predict exactly how things are going to continue to play out here, just given the environment. But we’re very encouraged by the trends that we’re seeing and we’re really pleased with our Consumables performance and it’s been a big focus for us and our team is performing well in this area.
Glen Santangelo — Guggenheim Securities — Analyst
Okay, thank you.
Operator
Your next question comes from Kevin Caliendo from UBS. Please go ahead. Your line is open.
Kevin Caliendo — UBS — Analyst
Hi, thanks. And thanks for taking my call. Maybe comment around strategic investments and the like going forward. The tone sounds a little bit different to me. Just wondering, is there opportunity? Where is the company looking? You’re obviously in a much better place financially than you have been over the last couple of years to maybe start being more aggressive, whether it’s M&A or partnerships. Where is the company looking to grow sort of externally?
Mark Walchirk — President and Chief Executive Officer
Yes, Kevin, thanks. I think you called it well. I think we’re certainly in a better position today to consider those types of strategic investments really centering on how can they help accelerate our growth and create value, not only for obviously our shareholders but also for our customers. And so we think there is opportunities that will exist.
As we look ahead, we’re in a better position to perhaps take advantage of some of those opportunities. And more specifically, as I mentioned earlier, again, how do we strengthen our capabilities, how do we expand our existing value proposition, how do we further invest in some of those areas that we believe create a distinct advantage for us, how do we continue to build scale in our businesses, are there market adjacencies or product adjacencies that would make sense, where we have a right to win and the opportunity to drive accretive growth and margin opportunities? Again, all with the goal of accelerating our growth, enhancing the value that we can provide to our customers and driving long-term shareholder value.
So those are, at a high level, obviously some of the areas that we’re looking at. And again, I don’t want to give you the impression that we’re taking our eye off the ball on what’s right in front of us here, but we’re also looking down the road and thinking about how we can continue to drive shareholder value over time.
Kevin Caliendo — UBS — Analyst
That’s helpful. And just, can you give us a reminder, I’m just — as we try to figure out the margin situation here, growth and operating margin, especially in Animal, what’s the delta between Companion and production in terms of the margins? Is there a meaningful difference between the two? So if one grows faster than the other, margin is impacted one way or the other?
Don Zurbay — Chief Financial Officer
No, I would say within Animal Health space, it’s relatively consistent. So there is not necessarily a product or interest segment mix component that you’d need to think about.
Kevin Caliendo — UBS — Analyst
Okay, that’s helpful. Thanks, guys.
Mark Walchirk — President and Chief Executive Officer
Thank you.
Operator
Your next question comes from Kevin Kedra from G.research. Please go ahead. Your line is open.
Kevin Kedra — G.research — Analyst
Hi, thanks for taking the questions. I want to bring it back to cash flow. You mentioned the payables shift over the past six months. Seems like receivables may have also been a bit of a headwind towards cash flow. How should we be thinking about those trends for the balance of the fiscal year?
Don Zurbay — Chief Financial Officer
Yes, thanks, Kevin. I think we’re back in balance. As we mentioned, accounts payable, we had pretty high-level accounts payable that we were managing at the beginning of the fiscal year. Those have normalized. So, I think we’re in a position now where you should look at free cash flow as kind of growing with the business as we move forward.
Kevin Kedra — G.research — Analyst
Okay. And then Mark, you mentioned the strategic opportunities as the potential use of cash. I know when you first came on, there were questions about the dividend and possibly eliminating the dividend at the time. Obviously, you guys have stood by it. And I think we’re at the opposite end of the question, which is, when do you guys start to think about perhaps returning that dividend to growth?
Mark Walchirk — President and Chief Executive Officer
Well, Don can certainly weigh in here as well. I think as we indicated in our prepared remarks, we continue and our Board continues to view the dividend as a very important part of returning cash to our shareholders. And certainly, that’s our point of view that we expect to continue at this point. Obviously, as things continue to evolve, we’ll look at those opportunities, but we believe strongly in the importance of our dividend.
Don Zurbay — Chief Financial Officer
Yes, I think as we emerge from the pandemic here, and you look at capital allocation, as Mark mentioned, I think we feel like there is good opportunity to deploy that capital into the M&A space, as an example. And so, we’d probably be looking at that before even looking at something different.
Kevin Kedra — G.research — Analyst
Great. Thanks.
Operator
Your next question comes from Jon Block from Stifel. Please go ahead. Your line is open.
Jon Block — Stifel — Analyst
Thanks. Hey, guys. And really nice quarter. Maybe two questions. One for Don, one for Mark. Don, I’ll start with you. The opex as a percent of sales of 15.3% versus — and I guess what was a normalized, call it, 18.2% last quarter. I just want to sort of push here. Is this a new level? Opex as a percent of sales was consistently in and around 17.5% or 18% of sales pre-COVID. And I’m just curious, have you guys throughout the pandemic been able to find sort of parts of the business where there was an ability to permanently reduce costs, calling without impairing the top line? And then I’ve just got a follow-up.
Don Zurbay — Chief Financial Officer
Yes, so good question. And we think so. I mean, I think as we move forward, we’re going to put that to the test a bit. But yes, we’ve been very disciplined on our expenses, particularly over the last couple of quarters. I think you’re also seeing that we felt like our cost structure was in a good position to leverage off higher sales volume. And so that’s playing out. But as I mentioned earlier, that I think that the pandemic has given us some new opportunities to look at, things that we’re benefiting from now and making those sustainable components of our expense structure or expense reductions that can help us.
Jon Block — Stifel — Analyst
Got it. That’s helpful. Great job. It’s been incredible to see. I think, Mark, just to shift to you. Fair to say a lot of people have walked — they’ve flooded back in the dental office over the past couple of months for hygiene, for catch up for hygiene. And then you got the talk of a vaccine in calendar 1Q or 2Q next year. And so, I’m just curious to get your thoughts. I mean, do you think there is a potential air pocket for the industry in the beginning of next calendar year? And I know it’s difficult to predict, but they come back running into the office in, call, July, September, October, talk of a vaccine, do you have any concerns about that air pocket early next year? Thanks for your time, guys.
Mark Walchirk — President and Chief Executive Officer
Yes, John. Thank you. Like you said, difficult to predict, right, because I think the situation with the pandemic is difficult to predict. But again, I think, as we’ve indicated, our dental customers, the dental offices have really taken really strong steps to put all the right safety measures and protocols into place to really ensure the health and safety of their patients and their staff as well, which is a critical component to it.
And so, I’m not sure in terms of specific air pocket and what we would predict there. We believe it’s very safe to go to the dentist. We believe oral health is a absolutely essential part of overall patient health, and so — look, I think as things continue to progress and we see a widespread distribution of the safe and effective vaccine, I think that’s going to be a key indicator. For some, some portion of the population have decided they’re not going back to the dentist yet, and I think that’s what we’re seeing in some of the patient demand external data. But again, our data would suggest patient demand is a bit higher than that and I think as soon as things continue to ease and open up and the vaccine situation improves and is used across a wide range of the population, I think we’ll see a nice opportunity for growth in the dental market going forward.
Jon Block — Stifel — Analyst
Thanks, Mark, and congrats on the progress.
Mark Walchirk — President and Chief Executive Officer
Thank you.
Operator
Your next question comes from Jason Bednar from Piper Sandler. Please go ahead. Your line is open.
Jason Bednar — Piper Sandler — Analyst
Yes. Good morning, guys. Thanks for taking the questions. And I’ll just echo the congrats on a nice quarter here. Mark, I wanted to go back to some comments you made on a couple of prior questions. I mean, you were comparing and contrasting some of your internal and external Dental data. Some of the external data here is showing a moderating of activity here over the last several weeks. But I mean, have you seen at all any moderation of activity from October to November in the internal data that you referenced?
Mark Walchirk — President and Chief Executive Officer
Well, I would say, very modest, if any, to directly answer your question. I think, look, we’re obviously keeping a very close watch on any potential State and local actions that maybe taken and look the situation with the virus is evolving on a daily and weekly basis. I mean, if you look at kind of the broader what’s happened across the industry over the last nine months, you have the sharp downturn, then the quick recovery periods kind of demand trends leveled off a bit. And could there be a slight moderation here again due to any potential State and local actions that may be taken? Perhaps. But as I indicated, we do not expect a broad shutdown of dental offices. It’s again, very safe to go to the dentist. And while we could see some perhaps a slight moderation here to the earlier discussion, the advancement of the vaccine, the wide distribution of that, we think that will be an important indicator as well as people feeling 100% comfortable to go back to the dentist. And frankly, you could see some pent-up demand as a result of that, as we head into ’21. But generally again, difficult to predict at this point.
Jason Bednar — Piper Sandler — Analyst
Okay. Yes, that’s fair and it’s helpful. Maybe the second questions from me, Mark — I mean, wondering if there’s anything you can share here regarding the Heartland Dental contract you have? I believe that contract is scheduled to expire at the end of the calendar year. When should we hear an update and maybe speak to your level of confidence in renewing that contract in a similar form as it currently exists?
Mark Walchirk — President and Chief Executive Officer
Yes, Jason. So, look, as we’ve said before, we don’t comment on specific customer negotiations or timing of agreements. We had a great relationship with Heartland. We consider it a privilege to support Heartland and their practices across the country and we believe we provide tremendous value to Heartland and their supported practices and really look forward to continuing to build on our relationship with Heartland going forward. So, we’re very pleased with, again, our relationship and looking forward to our continued growth and relationship with Heartland.
Jason Bednar — Piper Sandler — Analyst
Okay, understood. Thanks, Mark.
Operator
Your last question comes from Nathan Rich from Goldman Sachs. Please go ahead. Your line is open.
Nathan Rich — Goldman Sachs — Analyst
Thanks. Good morning and thanks for fitting me in. I wanted to go back to the Dental segment margins. I just have a bigger picture question. I guess if we look back a few years, those margins were north of 10%. You’re now kind of back to those levels as of the latest quarter. It sounds like you’ve been able to be opportunistic too when it comes to some of the opex savings that you’ve realized during the pandemic. So I guess, when we think about the outlook here, do you feel like a double-digit type operating margin for this segment is sustainable, especially as you continue to grow the business going forward?
Don Zurbay — Chief Financial Officer
Yes, thanks, Nathan. So, and as I mentioned, we’re going to be pretty disciplined here. I’m trying not to give absolute guidance or forward-looking type statements on that. But I would just say that, again what you’re seeing is good expense discipline. And really on dental side too, the leveraging impact we have with sales have been improving. You can see that the margin has gotten back into the double-digit territory. And I think those are, in our view, sustainable type items that could help support that.
Nathan Rich — Goldman Sachs — Analyst
Okay, that’s helpful. And then maybe just a quick follow-up going back to the share gains in Consumables. When you look across the various kind of customer segments that you serve between kind of individual practices, large DSOs, etc. Could you maybe just talk about the differences in performance that you’re seeing there and in terms of where the share gains are coming from?
Mark Walchirk — President and Chief Executive Officer
Yes, Nathan. Thanks. Look, I think our performance and our gains and the momentum is really going across the entire customer base, across the industry, so private practices, regional DSOs, national DSOs. We put a lot of increased focus on the DSO segment. We continue to invest in the sales and support teams that support those customers and their unique requirements, and we ultimately view that as the DSO market obviously represent strong growth opportunities, and we’ll continue to invest there.
So really, we see the momentum and the growth happening across the board and we’re pleased with that balance that we believe we’re generating through our broad customer base.
Nathan Rich — Goldman Sachs — Analyst
Great. Thanks for the time.
Don Zurbay — Chief Financial Officer
Thank you.
Operator
We are out of time for questions. I would like to turn the call back over to Mark Walchirk for any closing remarks.
Mark Walchirk — President and Chief Executive Officer
Great, thank you. Thanks, everyone, for your interest in Patterson Companies and we appreciate your time today and we look forward to hosting you again on our fiscal ’21 third quarter call. Until then, stay safe and I hope you and your families will have a happy holiday season. Thanks very much.
Operator
[Operator Closing Remarks]